SG10201802389SA - 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof - Google Patents

19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof

Info

Publication number
SG10201802389SA
SG10201802389SA SG10201802389SA SG10201802389SA SG10201802389SA SG 10201802389S A SG10201802389S A SG 10201802389SA SG 10201802389S A SG10201802389S A SG 10201802389SA SG 10201802389S A SG10201802389S A SG 10201802389SA SG 10201802389S A SG10201802389S A SG 10201802389SA
Authority
SG
Singapore
Prior art keywords
disubstituted
methods
steroids
pyrazolyl
pyrazolyl steroids
Prior art date
Application number
SG10201802389SA
Other languages
English (en)
Inventor
Gabriel Martinez Botella
Boyd L Harrison
Albert Jean Robichaud
Francesco G Salituro
Richard Thomas Beresis
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of SG10201802389SA publication Critical patent/SG10201802389SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201802389SA 2013-04-17 2014-04-17 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof SG10201802389SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013074323 2013-04-17

Publications (1)

Publication Number Publication Date
SG10201802389SA true SG10201802389SA (en) 2018-04-27

Family

ID=51730809

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201508550XA SG11201508550XA (en) 2013-04-17 2014-04-17 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
SG10201802389SA SG10201802389SA (en) 2013-04-17 2014-04-17 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201508550XA SG11201508550XA (en) 2013-04-17 2014-04-17 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof

Country Status (26)

Country Link
US (6) US9512165B2 (OSRAM)
EP (4) EP2986623B1 (OSRAM)
JP (7) JP6470258B2 (OSRAM)
KR (4) KR102396328B1 (OSRAM)
CN (4) CN105339381B (OSRAM)
AU (5) AU2014256229B2 (OSRAM)
BR (1) BR112015026380A8 (OSRAM)
CA (1) CA2909545A1 (OSRAM)
CY (2) CY1121228T1 (OSRAM)
DK (3) DK3498725T3 (OSRAM)
ES (3) ES3044385T3 (OSRAM)
HR (2) HRP20190232T1 (OSRAM)
HU (2) HUE041369T2 (OSRAM)
IL (4) IL286794B2 (OSRAM)
LT (2) LT3498725T (OSRAM)
MX (3) MX395023B (OSRAM)
PL (2) PL3498725T3 (OSRAM)
PT (2) PT2986623T (OSRAM)
RS (2) RS58297B1 (OSRAM)
RU (1) RU2675855C2 (OSRAM)
SG (2) SG11201508550XA (OSRAM)
SI (2) SI3498725T1 (OSRAM)
SM (2) SMT202100509T1 (OSRAM)
TR (1) TR201901745T4 (OSRAM)
WO (1) WO2014169833A1 (OSRAM)
ZA (1) ZA201507740B (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336930B (es) 2005-11-28 2016-02-05 Marinus Pharmaceuticals Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
CN104136452A (zh) 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
DK2806877T3 (da) 2012-01-23 2019-11-04 Sage Therapeutics Inc Neuroaktive steroidformuleringer omfattende et kompleks af allopregnanolon og sulfobutylether beta-cyclodekstrin
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
EP2986623B1 (en) 2013-04-17 2018-11-07 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
SI2986624T1 (sl) 2013-04-17 2020-10-30 Sage Therapeutics, Inc. 19-nor nevroaktivni steroidi za metode zdravljenja
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
JP6466942B2 (ja) 2013-08-23 2019-02-06 セージ セラピューティクス， インコーポレイテッド 向神経活性ステロイド、組成物、及びその使用
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP4527461A3 (en) 2014-10-16 2025-06-25 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
RS60642B1 (sr) 2014-10-16 2020-09-30 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
SMT202000276T1 (it) 2014-11-27 2020-07-08 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
CN104558092B (zh) * 2014-12-29 2017-01-18 北京理工大学 一种甾体皂苷化合物及其制备方法和用途
SMT202100113T1 (it) 2015-01-26 2021-05-07 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
CN104910236B (zh) * 2015-06-26 2016-08-17 西北农林科技大学农药研究所 吡唑基甾体衍生物及其制备方法、用途
MX2018004376A (es) 2015-10-16 2018-08-01 Marinus Pharmaceuticals Inc Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
IL264129B2 (en) * 2016-07-11 2024-05-01 Sage Therapeutics Inc C17, c20, and c21 substituted neuroactive steroids and their methods of use
NZ790187A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C7, C12, and C16 substituted neuroactive steroids and their methods of use
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
TWI854445B (zh) 2016-08-23 2024-09-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CA3060255A1 (en) * 2017-04-18 2018-10-25 Marinus Pharmaceuticals, Inc Sustained release injectable neurosteroid formulations
IL270962B2 (en) * 2017-06-01 2023-09-01 Sumitomo Chemical Co A heterocyclic compound and a mixture containing it
AU2018327357B2 (en) * 2017-09-07 2024-08-22 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US20220110949A1 (en) * 2017-09-14 2022-04-14 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20210228596A1 (en) * 2017-10-12 2021-07-29 Sage Therapeutics, Inc. Method of treating cns disorders with neurosteroids and gabaergic compounds
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
MA51315A (fr) * 2017-12-22 2020-10-28 Sage Therapeutics Inc Compositions et méthodes permettant de traiter des troubles du snc
EP3728285A1 (en) 2017-12-22 2020-10-28 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
MX2020008422A (es) * 2018-02-11 2020-09-21 Jiangsu Hansoh Pharmaceutical Group Co Ltd Regulador derivado de esteroides, metodo para prepararlos y usos de los mismos.
CN114085260B (zh) * 2018-02-11 2023-10-20 江苏豪森药业集团有限公司 甾族类衍生物调节剂、其制备方法和应用
EP3806863A1 (en) * 2018-06-12 2021-04-21 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CN111040015B (zh) * 2018-10-15 2022-03-18 南京诺瑞特医药科技有限公司 19-去甲-c21取代类固醇衍生物
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
IL312610A (en) 2018-12-05 2024-07-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CN113226326B (zh) 2018-12-17 2024-09-20 细胞内治疗公司 有机化合物
CN116059215B (zh) * 2019-01-08 2025-10-03 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
EP3911331A4 (en) * 2019-01-14 2023-01-18 Beijing Xuanyi Pharmasciences Co., Ltd. TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
WO2020155057A1 (zh) * 2019-01-31 2020-08-06 深圳仁泰医药科技有限公司 γ-氨基丁酸调节剂的晶型X及其制备方法和应用
JP2022532710A (ja) 2019-05-10 2022-07-19 ブリー バイオサイエンシーズ， インコーポレイテッド ブレキサノロン、ガナキソロン、またはズラノロンを含有する薬学的組成物、及びそれらの使用
WO2020242772A1 (en) 2019-05-28 2020-12-03 Teva Czech Industries S.R.O Solid state forms of sage-217 and processes for preparation thereof
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
CN114729000A (zh) 2019-06-27 2022-07-08 萨奇治疗股份有限公司 用于治疗cns病症的化合物
BR112021026447A2 (pt) * 2019-06-27 2022-04-12 Sage Therapeutics Inc Composições e métodos para tratamento de distúrbios de cns
CA3143509A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
JP7726867B6 (ja) * 2019-08-07 2025-09-18 上▲海▼翰森生物医▲薬▼科技有限公司 ステロイド誘導体調節因子の塩及び結晶形態
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CA3159087A1 (en) * 2019-09-30 2021-04-08 Eliem Therapeutics (UK) Ltd Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof
IL293510A (en) * 2019-12-05 2022-08-01 Sage Therapeutics Inc A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
AU2020395254A1 (en) 2019-12-06 2022-06-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
PE20221911A1 (es) * 2020-03-25 2022-12-23 Sage Therapeutics Inc Uso de agentes para el tratamiento de condiciones respiratorias
EP4181884A1 (en) * 2020-07-20 2023-05-24 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
IL304080A (en) * 2021-01-28 2023-08-01 Sage Therapeutics Inc Use of neuroactive steroids for treatment of sexual dysfunction
EP4308162A1 (en) 2021-03-17 2024-01-24 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
MX2023012727A (es) 2021-04-29 2023-11-08 Sage Therapeutics Inc Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.
MX2023012728A (es) 2021-04-29 2023-11-08 Sage Therapeutics Inc Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante.
CA3252357A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS FOR THE TREATMENT OF CNS DISORDERS
US20250177418A1 (en) 2022-02-28 2025-06-05 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
WO2024112759A1 (en) 2022-11-21 2024-05-30 Sage Therapeutics, Inc. Negative nmda-modulating compounds and methods of use thereof
WO2024189061A1 (en) 2023-03-14 2024-09-19 Curia Spain, S.A.U. Process and intermediates for the preparation of 3alpha-hydroxy-3beta-alkyl steroids
WO2024230797A1 (zh) 2023-05-11 2024-11-14 上海枢境生物科技有限公司 甾体类化合物、制备方法及其用途

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856415A (en) 1957-11-13 1958-10-14 Searle & Co 3,19-dihydroxy-5-androstene derivatives
FR1380417A (fr) 1962-05-15 1964-12-04 Roussel Uclaf Nouveaux androstanyl-pyrazoles et procédé de préparation
NL297205A (OSRAM) * 1962-08-28
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
US3511860A (en) * 1966-09-26 1970-05-12 Syntex Corp Synthesis of 19-nor and ring a aromatic steroids and intermediates therefor
NL6801449A (OSRAM) * 1968-02-01 1969-08-05
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1434919A (en) 1972-06-15 1976-05-12 Glaxo Lab Ltd 3alpha-hydroxy androstanes
GB1380246A (en) 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
US3983111A (en) 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
GB1436324A (en) 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
DK134348C (da) 1973-11-30 1977-03-21 Schering Ag Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
DE2438020A1 (de) 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
DE2526373C2 (de) 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
DE2632677A1 (de) 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4389345A (en) 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US4495102A (en) 1982-09-03 1985-01-22 G. D. Searle & Co. Aminoalkyl steroids
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA2118938A1 (en) 1991-09-13 1993-04-01 Kelvin W. Gee Novel gabaa receptor with steroid binding sites
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
DE69435286D1 (de) 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
CZ300694A3 (en) 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
US5567830A (en) 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
EP0752860B1 (en) 1994-02-14 2000-08-23 Euro-Celtique S.A. Androstanes and pregnanes for allosteric modulation of gaba receptor
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
AU3125695A (en) 1994-07-21 1996-02-22 Pharmacia & Upjohn Company Neurologically active aminosteroids
US5792757A (en) * 1994-08-04 1998-08-11 Pherin Pharmaceuticals 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function
CA2205919A1 (en) 1994-11-23 1996-05-30 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
DE69634039T2 (de) 1995-06-06 2005-12-08 Euro-Celtique S.A. Steroidderivate der Androstan- und der Pregnanreihe
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5935545A (en) 1997-07-11 1999-08-10 E. I. Du Pont De Nemours And Company Process for producing an aqueous solution comprising ferric chloride
IL146230A0 (en) * 1999-04-29 2002-07-25 Purdue Pharma Ltd 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
ES2243442T3 (es) 2000-02-18 2005-12-01 Taiho Pharmaceutical Company Limited Procedimiento de preparacion de derivados esteroides.
US6855836B2 (en) 2000-10-26 2005-02-15 Jenapharm Gmbh & Co. Kg 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
ES2287184T3 (es) 2000-11-03 2007-12-16 Washington University Estructuras aromaticas modificadas con sustituyentes hidroxi-, que tienen actividad citoprotectora.
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
AU2004224053B2 (en) 2003-03-24 2011-06-09 Sterix Limited Oestrogen derivatives as inhibitors of steroid sulphatase
WO2005000869A1 (en) 2003-05-29 2005-01-06 Washington University Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids
JP2007512344A (ja) 2003-11-24 2007-05-17 メルク　エンド　カムパニー　インコーポレーテッド エストロゲン受容体調節剤
US20090118248A1 (en) 2004-04-23 2009-05-07 Euro-Celtique S.A. 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
WO2006028963A2 (en) * 2004-09-03 2006-03-16 Celgene Corporation Substituted heterocyclic compounds and uses thereof
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
CA2582231A1 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
US8030298B2 (en) * 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
RS51304B (sr) 2005-06-09 2010-12-31 Euro-Celtique S.A. Farmaceutske kompozicije neuroaktivnog steroida i njihova upotreba
CN100362013C (zh) * 2006-03-16 2008-01-16 中国科学院上海有机化学研究所 一类c22-羰基甾体化合物、合成方法及其用途
CN101432274A (zh) * 2006-04-05 2009-05-13 惠氏公司 作为5-羟色胺-6配体的磺酰基-3-杂环吲唑衍生物
CN101506221B (zh) * 2006-09-19 2012-09-12 索尔瓦药物有限公司 雌三烯衍生物及其作为17β-羟基类固醇脱氢酶抑制剂的用途
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
WO2008157460A1 (en) 2007-06-15 2008-12-24 Cook, Kevin, M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101412742B (zh) 2007-10-19 2013-07-31 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
KR100958286B1 (ko) * 2007-11-15 2010-05-19 한국과학기술원 ａ１Ｇ Ｔ―타입 칼슘 채널을 억제하여 본태성 진전증을예방 및 치료하는 방법
US20090264443A1 (en) 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CN101624414B (zh) 2008-07-07 2013-02-13 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
CZ2008434A3 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
WO2010054158A2 (en) 2008-11-07 2010-05-14 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
WO2011079047A1 (en) 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
EP2598513A1 (en) 2010-07-30 2013-06-05 Medexis S.A. Compounds and methods for treating neoplasia
EP2667876A2 (en) 2010-12-15 2013-12-04 Harbor BioSciences, Inc. Methods and compounds for preparing 3alpha-oxygen substituted steroids
CA2828047C (en) 2011-02-15 2020-03-10 Socpra Sciences Et Genie, S.E.C. Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
CZ201181A3 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
ES2657986T3 (es) 2011-03-23 2018-03-07 Etsuro Ito Método y kit para la medición de muy alta sensibilidad de proteína y ácido nucleico y un novedoso sustrato enzimático
EP2736919A4 (en) 2011-07-29 2015-01-14 Univ California NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
JP6205362B2 (ja) * 2011-09-08 2017-09-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用
CN104136452A (zh) 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
DK2806877T3 (da) 2012-01-23 2019-11-04 Sage Therapeutics Inc Neuroaktive steroidformuleringer omfattende et kompleks af allopregnanolon og sulfobutylether beta-cyclodekstrin
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT3336097T (pt) 2012-06-19 2020-10-29 Intercept Pharmaceuticals Inc Preparação da forma não cristalina de ácido obeticólico
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
WO2014058736A1 (en) 2012-10-08 2014-04-17 Washington University Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EP2916846B1 (en) 2012-11-09 2025-09-17 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
JP2016501876A (ja) 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
RS57390B1 (sr) 2012-12-18 2018-09-28 Univ Washington Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja
US8939545B2 (en) 2012-12-20 2015-01-27 Eastman Kodak Company Inkjet printing with managed airflow for condensation control
CA2831054C (en) 2013-01-09 2016-08-30 Sapna Life Sciences Corp. Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
GB201302368D0 (en) 2013-02-11 2013-03-27 Univ Bath Compound
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
EP2986623B1 (en) 2013-04-17 2018-11-07 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
SI2986624T1 (sl) 2013-04-17 2020-10-30 Sage Therapeutics, Inc. 19-nor nevroaktivni steroidi za metode zdravljenja
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
JP6466942B2 (ja) 2013-08-23 2019-02-06 セージ セラピューティクス， インコーポレイテッド 向神経活性ステロイド、組成物、及びその使用
TWI839649B (zh) 2014-05-29 2024-04-21 美商賽吉醫療公司 神經活性類固醇，其組合物及其用途
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2016036724A1 (en) 2014-09-02 2016-03-10 The Texas A&M University System Method of treating organophosphate intoxication
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP4527461A3 (en) 2014-10-16 2025-06-25 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
RS60642B1 (sr) 2014-10-16 2020-09-30 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
SMT202000276T1 (it) 2014-11-27 2020-07-08 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
SMT202100113T1 (it) 2015-01-26 2021-05-07 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
WO2016164763A1 (en) 2015-04-10 2016-10-13 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
UY36741A (es) 2015-06-21 2016-12-30 Prevacus Inc Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
JP2018526423A (ja) 2015-09-08 2018-09-13 ビューポイント セラピューティクス， インコーポレイテッド 眼科疾患を処置するための化合物および製剤
MX2018004376A (es) 2015-10-16 2018-08-01 Marinus Pharmaceuticals Inc Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
US20200306262A1 (en) 2015-11-20 2020-10-01 Sage Therapeutics, Inc. Compounds and methods of their use
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
NZ790187A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C7, C12, and C16 substituted neuroactive steroids and their methods of use
IL264129B2 (en) 2016-07-11 2024-05-01 Sage Therapeutics Inc C17, c20, and c21 substituted neuroactive steroids and their methods of use
TWI854445B (zh) 2016-08-23 2024-09-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
CN111065394B (zh) 2017-08-31 2023-03-31 武田药品工业株式会社 中枢神经系统病症的治疗
AU2018327357B2 (en) 2017-09-07 2024-08-22 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019051477A1 (en) 2017-09-11 2019-03-14 Sage Therapeutics, Inc. METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
US20220110949A1 (en) 2017-09-14 2022-04-14 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
SG10202110563YA (en) 2017-11-10 2021-11-29 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disoders
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
MA51315A (fr) 2017-12-22 2020-10-28 Sage Therapeutics Inc Compositions et méthodes permettant de traiter des troubles du snc
EP3728285A1 (en) 2017-12-22 2020-10-28 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
AU2019264032A1 (en) 2018-05-04 2020-12-03 Acerus Pharmaceuticals Corporation Neurosteroid derivatives and uses thereof
EP3806863A1 (en) 2018-06-12 2021-04-21 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
BR112021009428A2 (pt) 2018-10-12 2021-08-31 Sage Therapeutics, Inc. Esteroides neuroativos substituídos na posição 10 por um grupo cíclico para uso no tratamento de distúrbios do cns
CA3116892A1 (en) 2018-10-19 2020-04-23 Sage Therapeutics, Inc. 9(11)-unsaturated neuroactive steroids and their methods of use
IL312610A (en) 2018-12-05 2024-07-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
AU2019403415B2 (en) 2018-12-21 2025-08-21 Sage Therapeutics, Inc. 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
TW202523658A (zh) 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
CN114729000A (zh) 2019-06-27 2022-07-08 萨奇治疗股份有限公司 用于治疗cns病症的化合物
CA3143509A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
BR112021026447A2 (pt) 2019-06-27 2022-04-12 Sage Therapeutics Inc Composições e métodos para tratamento de distúrbios de cns
IL293510A (en) 2019-12-05 2022-08-01 Sage Therapeutics Inc A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CN115551874A (zh) 2020-03-18 2022-12-30 萨奇治疗股份有限公司 神经活性类固醇及其使用方法
PE20221911A1 (es) 2020-03-25 2022-12-23 Sage Therapeutics Inc Uso de agentes para el tratamiento de condiciones respiratorias
EP4172171A1 (en) 2020-06-24 2023-05-03 Sage Therapeutics, Inc. 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof
EP4181884A1 (en) 2020-07-20 2023-05-24 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
IL303101A (en) 2020-11-25 2023-07-01 Sage Therapeutics Inc Compositions and methods for treating cns disorders
IL304080A (en) 2021-01-28 2023-08-01 Sage Therapeutics Inc Use of neuroactive steroids for treatment of sexual dysfunction
US20240148756A1 (en) 2021-02-18 2024-05-09 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
EP4308162A1 (en) 2021-03-17 2024-01-24 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
EP4322960A1 (en) 2021-04-12 2024-02-21 Sage Therapeutics, Inc. Treatment of essential tremor
MX2023012728A (es) 2021-04-29 2023-11-08 Sage Therapeutics Inc Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante.
MX2023012727A (es) 2021-04-29 2023-11-08 Sage Therapeutics Inc Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.
CA3252357A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS FOR THE TREATMENT OF CNS DISORDERS
US20250177418A1 (en) 2022-02-28 2025-06-05 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Also Published As

Publication number Publication date
CN108440633B (zh) 2021-07-13
US12201640B2 (en) 2025-01-21
PT2986623T (pt) 2019-02-06
AU2014256229A9 (en) 2016-03-17
PL2986623T3 (pl) 2019-04-30
US20170246191A1 (en) 2017-08-31
MX362543B (es) 2019-01-24
JP2019001807A (ja) 2019-01-10
CA2909545A1 (en) 2014-10-23
KR20220062690A (ko) 2022-05-17
US10172871B2 (en) 2019-01-08
DK3909966T3 (da) 2025-09-29
JP6470258B2 (ja) 2019-02-13
IL278487B (en) 2021-10-31
RU2018143835A (ru) 2019-01-16
AU2018278844B2 (en) 2020-07-16
CN105339381B (zh) 2018-04-27
IL286794B2 (en) 2024-06-01
US10342810B2 (en) 2019-07-09
ZA201507740B (en) 2017-09-27
SI3498725T1 (sl) 2021-11-30
US20220110950A1 (en) 2022-04-14
DK3498725T3 (da) 2021-08-30
KR20230172622A (ko) 2023-12-22
HUE041369T2 (hu) 2019-05-28
AU2022205157B2 (en) 2024-09-19
US9512165B2 (en) 2016-12-06
RU2675855C2 (ru) 2018-12-25
ES2709434T3 (es) 2019-04-16
EP3909966B1 (en) 2025-07-09
JP2025060975A (ja) 2025-04-10
US20200155576A1 (en) 2020-05-21
US11241446B2 (en) 2022-02-08
HK1224301A1 (en) 2017-08-18
EP3498725A1 (en) 2019-06-19
AU2014256229A1 (en) 2015-11-05
SG11201508550XA (en) 2015-11-27
RS62312B1 (sr) 2021-09-30
JP2018199716A (ja) 2018-12-20
EP2986623B1 (en) 2018-11-07
JP7527318B2 (ja) 2024-08-02
JP7085601B2 (ja) 2022-06-16
HUE055554T2 (hu) 2021-12-28
RU2015149008A (ru) 2017-05-22
ES2886182T3 (es) 2021-12-16
IL242089B (en) 2020-11-30
US20160108080A1 (en) 2016-04-21
EP3498725B1 (en) 2021-06-09
AU2018278844A1 (en) 2019-01-03
NZ713303A (en) 2021-03-26
EP2986623A4 (en) 2016-09-28
AU2022205157A1 (en) 2022-07-28
LT2986623T (lt) 2019-02-25
SMT202100509T1 (it) 2021-11-12
AU2014256229B2 (en) 2018-10-04
RS58297B1 (sr) 2019-03-29
CN113527400B (zh) 2024-06-28
AU2020256400A1 (en) 2020-11-12
JP2022058758A (ja) 2022-04-12
EP2986623A1 (en) 2016-02-24
IL310348A (en) 2024-03-01
HRP20211314T1 (hr) 2021-11-26
SMT201900066T1 (it) 2019-02-28
WO2014169833A1 (en) 2014-10-23
MX395023B (es) 2025-03-24
JP2021001220A (ja) 2021-01-07
US20180311262A1 (en) 2018-11-01
CY1125416T1 (el) 2023-03-24
EP4640277A3 (en) 2025-12-31
JP7668850B2 (ja) 2025-04-25
CN105339381A (zh) 2016-02-17
CN118754924A (zh) 2024-10-11
EP3909966A1 (en) 2021-11-17
SI2986623T1 (sl) 2019-03-29
PL3498725T3 (pl) 2021-11-08
HRP20190232T1 (hr) 2019-03-22
TR201901745T4 (tr) 2019-03-21
IL286794A (en) 2021-10-31
KR102396328B1 (ko) 2022-05-10
KR20150143690A (ko) 2015-12-23
JP2023154010A (ja) 2023-10-18
DK2986623T3 (en) 2019-03-04
ES3044385T3 (en) 2025-11-26
JP6784735B2 (ja) 2020-11-11
LT3498725T (lt) 2021-09-27
PT3498725T (pt) 2021-09-09
KR20210041121A (ko) 2021-04-14
US20250319106A1 (en) 2025-10-16
MX2015014600A (es) 2016-03-03
AU2024278325A1 (en) 2025-01-09
BR112015026380A2 (pt) 2017-07-25
AU2020256400B2 (en) 2022-04-28
IL286794B1 (en) 2024-02-01
BR112015026380A8 (pt) 2019-12-31
JP6710730B2 (ja) 2020-06-17
CY1121228T1 (el) 2020-05-29
CN108440633A (zh) 2018-08-24
KR102614507B1 (ko) 2023-12-19
CN113527400A (zh) 2021-10-22
WO2014169833A9 (en) 2016-03-03
EP4640277A2 (en) 2025-10-29
KR102239541B1 (ko) 2021-04-14
JP2016517851A (ja) 2016-06-20
MX2022007490A (es) 2022-07-05

Similar Documents

Publication Publication Date Title
IL286794A (en) 19- nor c3, 3- dimethomer c21- n- pyrazole Steroids and methods of using them
IL280155A (en) Anti- SIGLEC-8 antibodies and methods of using them
EP3932932B8 (en) Neuroactive steroids and methods of use thereof
PT2986624T (pt) Esteroides neuroativos 19-nor para métodos de tratamento
PT3406633T (pt) Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos
ZA201708412B (en) Neuroactive steroid solutions and their methods of use
EP3060253A4 (en) ANTI-Ly6E ANTIBODIES AND METHODS OF USE
PL2988764T3 (pl) Kompozycje przeciwłupieżowe i sposoby ich zastosowania
IL242943A0 (en) A process for the preparation of abiraterone and its intermediates
IL241768B (en) 2beta, 3alpha, 5alpha-trihydroxy-androstane-6-one, methods for its preparation and uses
IL243790A0 (en) Devices, kits and methods of connection